In summary, this study has identified and validated a castPCRTM assay for detecting the AKT1 E17K mutation in FFPE breast and gynecological tumor tissue samples, and subsequently confirmed the suitability of the OncoBEAMTM assay for AKT1 E17K mutation detection in plasma samples of advanced metastatic breast cancer patients. Here, AKT1 is linked to female reproductive system neoplasm.